Skip to main content
Premium Trial:

Request an Annual Quote

Scripps Translational Science Institute Awarded $34M in NIH Funding

NEW YORK (GenomeWeb) – The Scripps Translational Science Institute (STSI) announced today that it has been awarded $34 million in renewed funding from the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS).

According to STSI, this newest Clinical and Translational Science Award (CTSA) is the third five-year award it has received from the NCATS since 2008, and will be used to continue the institute's efforts to combine genomic and digital technologies with bioinformatics to advance medical research and clinical care.

As part of the award, STSI will work with Rady Children's Institute for Genomic Medicine on ultra-rapid whole-genome sequencing programs in acutely ill infants, and collaborate with the California Institute for Biomedical Research (Calibr) on drug discovery for unmet medical needs. Both STSI and Calibr are affiliates of the Scripps Research Institute.

"Genomic medicine research programs at STSI and [Rady Children's] synergize significantly, especially as related to the genetics of rare and infectious diseases," Rady Children's President and CEO Stephen Kingsmore said in a statement.

"We are thrilled to enable the broader Scripps Research mission by partnering with STSI to engage the CTSA network, bringing to bear drug discovery tools that could enable rapid translation of new therapeutic approaches to patients," Calibr Chief Operating Officer Matt Tremblay added.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.